Arkolith/Insider Trading/SABS/Form 4

Ellias Helen K.

DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Nov 28, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 24, 2023Option exercise(M)2.9M——2.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 24, 2023Option exercise(M)2K$1000.00$1.8M0

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-066394) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML